, Figure 2. a) TPA decrease from baseline during follow-up. b) absolute TPA value during follow-up. c) BMI decrease during follow-up. d) Loss of weight during follow-up

L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.65, issue.1, pp.5-29, 2015.

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al.,

, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, issue.11, pp.2913-2934, 2014.

M. Malvezzi, P. Bertuccio, and T. Rosso, European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?, Ann Oncol, vol.26, issue.4, pp.779-86, 2015.

H. J. Andreyev, A. R. Norman, J. Oates, and D. Cunningham, Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, vol.34, issue.4, pp.503-512, 1998.

Y. Choi, T. Kim, and K. Lee, The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy, J Pain Symptom Manage, vol.48, issue.1, pp.13-25, 2014.

S. Blauwhoff-buskermolen, K. S. Versteeg, M. Schueren, and . De-van-der,

, Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer, J Clin Oncol, vol.34, issue.12, pp.1339-1383, 2016.

K. Fearon, F. Strasser, and S. D. Anker, Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.5, pp.489-95, 2011.

R. N. Baumgartner, K. M. Koehler, and D. Gallagher, Epidemiology of Sarcopenia among the Elderly in New Mexico, Am J Epidemiol, vol.147, issue.8, pp.755-63, 1998.

J. R. Lieffers, O. F. Bathe, K. Fassbender, M. Winget, and V. E. Baracos, Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery, Br J Cancer, vol.107, issue.6, pp.931-937, 2012.

T. Voron, L. Tselikas, and D. Pietrasz, Sarcopenia Impacts on Short-and Long-term Results of Hepatectomy for Hepatocellular Carcinoma, Ann Surg, vol.261, issue.6, pp.1173-83, 2015.

S. L. Gomez-perez, J. M. Haus, and P. Sheean, Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ, J Parenter Enter Nutr, vol.40, issue.3, pp.308-326, 2016.

L. Martin, L. Birdsell, and N. Macdonald, Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index, J Clin Oncol, vol.31, issue.12, pp.1539-1586, 2013.

B. Tan, L. A. Birdsell, L. Martin, V. E. Baracos, and K. Fearon, Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clin Cancer Res, vol.15, issue.22, pp.6973-6982, 2009.

T. M. Pawlik, A. L. Gleisner, and J. L. Cameron, Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer, Surgery, vol.141, issue.5, pp.610-618, 2007.

M. B. Slidell, D. C. Chang, and J. L. Cameron, Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis, Ann Surg Oncol, vol.15, issue.1, pp.165-74, 2008.

A. C. Berger, J. C. Watson, E. A. Ross, and J. P. Hoffman, The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma, Am Surg, vol.70, issue.3, pp.235-275, 2004.

D. K. Chang, A. L. Johns, and N. D. Merrett, Margin clearance and outcome in resected pancreatic cancer, J Clin Oncol, vol.27, issue.17, pp.2855-62, 2009.

A. C. Berger, M. Garcia, and J. P. Hoffman, Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704, J Clin Oncol, vol.26, issue.36, pp.5918-5940, 2008.
DOI : 10.1200/jco.2008.18.6288

URL : http://europepmc.org/articles/pmc2645109?pdf=render

T. Conroy, F. Desseigne, and M. Ychou, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1842, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

S. Gourgou-bourgade, C. Bascoul-mollevi, and F. Desseigne, Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial, World Health Organ Tech Rep Ser, vol.31, issue.1, pp.1-253, 2000.
URL : https://hal.archives-ouvertes.fr/hal-01795555

G. Molenberghs and G. Verbeke, Linear Mixed Models for Longitudinal Data, 2000.

T. Therneau, Extending the Cox model, Mayo Clinic, 1996.
DOI : 10.1007/978-1-4684-6316-3_5

W. Sauerbrei and M. Schumacher, A bootstrap resampling procedure for model building: application to the Cox regression model, Stat Med, vol.11, issue.16, pp.2093-109, 1992.
DOI : 10.1002/sim.4780111607

S. M. Snapinn, Q. Jiang, and B. Iglewicz, Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator, Am Stat, vol.59, issue.4, pp.301-308, 2005.

P. E. Shrout and J. L. Fleiss, Intraclass correlations: uses in assessing rater reliability, Psychol Bull, vol.86, issue.2, pp.420-428, 1979.
DOI : 10.1037//0033-2909.86.2.420

J. L. Fleiss, Statistical methods for rates and proportions, pp.38-46

N. Mitsiopoulos, R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher et al., Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography, J Appl Physiol, vol.85, issue.1, pp.115-137, 1998.
DOI : 10.1152/jappl.1998.85.1.115

C. M. Prado, J. R. Lieffers, and L. J. Mccargar, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, vol.9, issue.7, pp.629-664, 2008.

M. Mourtzakis, C. Prado, J. R. Lieffers, T. Reiman, L. J. Mccargar et al., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, vol.33, issue.5, pp.997-1006, 2008.

N. Amini, G. Spolverato, and R. Gupta, Impact Total Psoas Volume on Short-and LongTerm Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia, J Gastrointest Surg, vol.19, issue.9, pp.1593-602, 2015.

Y. Choi, D. Oh, and T. Kim, Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index, PLoS ONE, vol.10, issue.10, 2015.

I. Park, S. J. Choi, and Y. S. Kim, Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with GemcitabineBased Chemotherapy, Cancer Res Treat, 2016.
DOI : 10.4143/crt.2015.250

URL : http://e-crt.org/upload/pdf/crt-2015-060.pdf

,

, Références de la thèse

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al.,

, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, issue.11, pp.2913-2934, 2014.

L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.65, issue.1, pp.5-29, 2015.

M. Malvezzi, P. Bertuccio, and T. Rosso, European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?, Ann Oncol, vol.26, issue.4, pp.779-86, 2015.

H. J. Andreyev, A. R. Norman, J. Oates, and D. Cunningham, Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, vol.34, issue.4, pp.503-512, 1998.

Y. Choi, T. Kim, and K. Lee, The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy, J Pain Symptom Manage, vol.48, issue.1, pp.13-25, 2014.

S. Blauwhoff-buskermolen, K. S. Versteeg, M. Schueren, and . De-van-der, Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer, J Clin Oncol, vol.34, issue.12, pp.1339-1383, 2016.

K. Fearon, F. Strasser, and S. D. Anker, Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.5, pp.489-95, 2011.

R. N. Baumgartner, K. M. Koehler, and D. Gallagher, Epidemiology of Sarcopenia among the Elderly in New Mexico, Am J Epidemiol, vol.147, issue.8, pp.755-63, 1998.

J. R. Lieffers, O. F. Bathe, K. Fassbender, M. Winget, and V. E. Baracos, Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery, Br J Cancer, vol.107, issue.6, pp.931-937, 2012.

T. Voron, L. Tselikas, and D. Pietrasz, Sarcopenia Impacts on Short-and Long-term Results of Hepatectomy for Hepatocellular Carcinoma, Ann Surg, vol.261, issue.6, pp.1173-83, 2015.

S. L. Gomez-perez, J. M. Haus, and P. Sheean, Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ, J Parenter Enter Nutr, vol.40, issue.3, pp.308-326, 2016.

L. Martin, L. Birdsell, and N. Macdonald, Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index, J Clin Oncol, vol.31, issue.12, pp.1539-1586, 2013.

B. Tan, L. A. Birdsell, L. Martin, V. E. Baracos, and K. Fearon, Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clin Cancer Res, vol.15, issue.22, pp.6973-6982, 2009.

D. Gupta and C. G. Lis, Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature, Nutr J, vol.9, p.69, 2010.

C. Afaneh, D. Gerszberg, E. Slattery, D. S. Seres, J. A. Chabot et al., Pancreatic cancer surgery and nutrition management: a review of the current literature, Hepatobiliary Surg Nutr, vol.4, issue.1, pp.59-71, 2015.

J. S. Temel, J. A. Greer, and S. Admane, Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non-Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care, J Clin Oncol, vol.29, issue.17, pp.2319-2345, 2011.

I. R. Cho, M. J. Chung, and S. Bang, Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer, Pancreatol Off J Int Assoc Pancreatol IAP Al, vol.13, issue.5, pp.539-582, 2013.

H. Oettle, P. Neuhaus, and A. Hochhaus, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, vol.310, issue.14, pp.1473-81, 2013.

K. K. Christians, S. Tsai, and A. Mahmoud, Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?, The Oncologist, vol.19, issue.3, pp.266-74, 2014.

, Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDASPRODIGE 44)-Full Text View-ClinicalTrials, 2016.

H. A. Burris, M. J. Moore, and J. Andersen, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, issue.6, pp.2403-2416, 1997.

M. Ychou, T. Conroy, and J. F. Seitz, An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.14, issue.3, pp.481-490, 2003.

T. Conroy, B. Paillot, and E. François, Irinotecan plus oxaliplatin and leucovorinmodulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.6, pp.1228-1264, 2005.

T. Conroy, F. Desseigne, and M. Ychou, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1842, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

, Cancer du pancréas | SNFGE.org-Société savante médicale française d'hépatogastroentérologie et d'oncologie digestive, 2016.

A. Francis, I. R. Chari, and S. T. , Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association, Gastroenterology, vol.146, issue.1, pp.291-304, 2014.

M. Ducreux, A. S. Cuhna, and C. Caramella, Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.56-68, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01810223

J. A. Pietryga and D. E. Morgan, Imaging preoperatively for pancreatic adenocarcinoma, J Gastrointest Oncol, vol.6, issue.4, pp.343-57, 2015.

S. M. Schneider, A. , R. Filippi, and J. , Sarcopenia is prevalent in patients with Crohn's disease in clinical remission, Inflamm Bowel Dis, vol.14, issue.11, pp.1562-1570, 2008.

P. Peng, O. Hyder, and A. Firoozmand, Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma, J Gastrointest Surg Off J Soc Surg Aliment Tract, vol.16, issue.8, pp.1478-86, 2012.

N. Amini, G. Spolverato, and R. Gupta, Impact Total Psoas Volume on Short-and LongTerm Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia, J Gastrointest Surg, vol.19, issue.9, pp.1593-602, 2015.

Y. Choi, D. Oh, and T. Kim, Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index, PLoS ONE, vol.10, issue.10, 2015.

I. Park, S. J. Choi, and Y. S. Kim, Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with GemcitabineBased Chemotherapy, Cancer Res Treat, 2016.

,

J. L. Fleiss, Statistical methods for rates and proportions, pp.38-46

A. Lambert, Outil de calcul du score de TPA (Total Psoas Area) en ligne

J. S. Temel, A. P. Abernethy, and D. C. Currow, Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials, Lancet Oncol, vol.17, issue.4, pp.519-550, 2016.